Blog / tracking
PT-141 Research Explained: What the RECONNECT Trials Show and What to Track
What the bremelanotide (PT-141) RECONNECT trials and FDA label report, the side effects described, and what to track if your provider prescribed it.
By Peppy Team6 min read
PT-141 is one of the better known peptides outside the weight loss world. Its generic name is bremelanotide, and unlike many peptides people read about online, it has gone through large phase 3 trials and has an FDA approved form. That makes it a useful example of what solid peptide research looks like, and what a good record around it might include.
This guide walks through what PT-141 is, what the main trials reported, which side effects the research and label describe, and what is worth writing down if a licensed provider has prescribed it for you. It is general education, not medical advice, and it does not suggest any dose or schedule.
What PT-141 is
Bremelanotide is a synthetic peptide that acts on melanocortin receptors, a group of receptors in the body and brain involved in several signaling pathways. The FDA label for Vyleesi (bremelanotide) injection on DailyMed describes it as a melanocortin receptor agonist.
The approved use is narrow. According to that label, it is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). That means low sexual desire that causes marked distress or difficulty in a relationship, and that is not explained by another medical or psychiatric condition, relationship problems, or the effects of another medication.
A few things stand out about it compared with most peptides people track:
- It is used as needed, not on a fixed daily or weekly routine.
- The approved product comes as a prefilled autoinjector, not a vial you mix yourself.
- The label sets clear limits on how often it can be used, which your provider will explain.
Because of that as-needed pattern, a record looks a little different from a GLP-1 log, where doses land on the same day each week.
What the RECONNECT trials found
Most of what we know about bremelanotide comes from a pair of identical phase 3 trials called RECONNECT, studies 301 and 302.
The main 24 week studies
The results were published by Kingsberg and colleagues in Obstetrics and Gynecology in 2019. Here is a plain summary of what the paper reports:
- 1,267 premenopausal women with HSDD were randomized to bremelanotide or placebo for 24 weeks.
- The treatment was given under the skin, as needed.
- The main measures were a desire score from the Female Sexual Function Index and a distress score from the Female Sexual Distress Scale.
- In both studies, the bremelanotide group showed statistically significant improvements in desire and reductions in related distress compared with placebo.
- Nausea, flushing and headache were more common with bremelanotide, each seen in 10% or more of participants in both studies.
The changes were statistically significant, but the average differences from placebo were fractions of a point on these scales (for example, 0.35 on the desire score across both studies). Whether it makes sense for an individual is a conversation for a licensed provider.
The 52 week extension
Women who finished the main studies could join a 52 week open label extension. In open label studies everyone knows they are getting the active treatment, so results are less certain than in a blinded trial.
The extension was reported by Simon and colleagues, also in 2019. Of 856 eligible women, 684 joined and 272 completed it. The authors reported no new safety signals and described sustained improvements in desire and distress scores. The most common treatment related side effects were nausea (40.4%), flushing (20.6%) and headache (12.0%).
Side effects the label describes
The FDA label adds detail that matters for anyone keeping a health record. These points come straight from the label linked above:
- Blood pressure and heart rate. The label says a temporary rise in blood pressure and drop in heart rate occurs after each dose and usually resolves within 12 hours. It lists uncontrolled high blood pressure and known cardiovascular disease as reasons not to use it.
- Nausea. Reported by 40% of patients in the trials. The label notes it improved for most patients with the second dose, but some needed anti-nausea treatment and some stopped early.
- Darkening of the skin. Focal hyperpigmentation, including on the face and gums, was reported by about 1% of patients. The label says the risk was higher with daily use and in people with darker skin, and that it did not always go away.
- Interactions. The label warns that bremelanotide may slow stomach emptying and can lower levels of some oral medicines, including oral naltrexone.
What to track if your provider prescribed PT-141
An as-needed peptide is easy to lose track of. There is no fixed day to anchor your memory, and weeks can pass between uses. A short, consistent record fixes that.
The basics for each use
Keep each entry simple:
- Date and time.
- The dose your provider gave you, exactly as they wrote it.
- Injection site, such as left thigh or right side of the abdomen.
- Anything unusual about that dose, like a missed or partial injection.
Over a month, these entries show your provider how often you actually used it. That matters because the label sets limits on frequency, and memory is not a reliable way to count.
Side effects and how long they last
Since nausea, flushing and headache were the most common side effects in the trials, note:
- Which side effect you noticed, if any.
- How strong it felt, on a simple mild, moderate or severe scale.
- Roughly how long it lasted.
Because the label mentions a short rise in blood pressure, some providers may ask patients to keep home blood pressure readings. If yours does, log each reading with the time and how long it was after the dose. Do not change anything on your own based on a reading. Bring the record to your provider.
Skin changes and other medicines
Since the label mentions skin darkening, a dated note or photo of any new dark spot gives your provider something concrete to look at. It also helps to keep a list of other medicines you take, especially oral ones, since the label flags possible interactions.
If your provider gave you a vial
The approved product is a prefilled autoinjector, so most people never have to work out any numbers. If your provider or pharmacy gave you a vial instead, the math of concentration, volume and syringe units applies. Our free peptide calculator shows how the vial strength, the water added and the dose your provider gave you turn into units on a U-100 syringe. It only converts the numbers you enter and never suggests a dose. For more on vial records, see how to enter your vial and dose.
Keeping a record in Peppy
Peppy is a peptide tracker app for iPhone that keeps this kind of record in one place. PT-141 is in its library of peptides, so you can log each use with the dose your provider gave you and see it in your dose history. The injection site rotation body map shows which sites have rested, and side effect check-ins sit next to your doses, as explained in weight, side effects and history.
Everything stays on your iPhone and your own iCloud backup, with no account needed.
The short version
- PT-141, or bremelanotide, is a melanocortin receptor agonist with an FDA approved form for a specific condition in premenopausal women.
- Two phase 3 RECONNECT trials reported statistically significant improvements in desire and distress scores compared with placebo.
- Nausea, flushing and headache were the most common side effects, and the label also describes a short rise in blood pressure, rare skin darkening, and possible interactions with some oral medicines.
- Because it is used as needed, a simple log of each use, side effects and any readings your provider asks for is the best way to give them an accurate picture.
Every decision about whether to use it, and how, belongs to you and a licensed healthcare provider.
More from the blog

dose log6 min read
BPC-157 Tracker: Logging Injections, Sites and How You Feel
A practical guide to using a BPC-157 tracker: what to log at every injection, how to keep vial math straight and how to record sites and symptoms.
- dose log
- injection sites
- vials

tracking6 min read
SS-31 Research Explained: What Elamipretide Studies Show and What to Track
What human trials of SS-31 (elamipretide) report, what the 2025 FDA decision means, and what to keep in your peptide tracker.
- tracking
- dose log
- injection sites

glp 16 min read
What Orforglipron Research Shows About Oral GLP-1 Pills and What to Track
A plain guide to the ATTAIN-1 and ACHIEVE-1 orforglipron trials, how a daily GLP-1 pill differs from injectables, and what to record.
- glp 1
- dose log
- side effects
